# EDGAR Filing Document

**Accession Number:** 0001638287
**File Stem:** 0001104659-25-066403
**Filing Date:** 2025-7
**Character Count:** 2961
**Document Hash:** 9e9d08723300afe60d7bf71ac447716e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-066403.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001104659-25-066403

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250708

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MetaVia Inc.
- **CENTRAL INDEX KEY:** 0001638287
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472389984
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 545 CONCORD AVENUE
- **STREET 2:** SUITE 210
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138
- **BUSINESS PHONE:** (857) 702-9600

**MAIL ADDRESS:**
- **STREET 1:** 545 CONCORD AVENUE
- **STREET 2:** SUITE 210
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NeuroBo Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20191231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Gemphire Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20150331

![](tm2518126d4_correspimg01.jpg)

July 8, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, NE

Washington, D.C. 20549

Attention: Tyler Howes

---

| | |
|:---|:---|
| **Re:** | **MetaVia Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **File No. 333-288486** |
|  | **Acceleration Request** |

---

---

| | |
|:---|:---|
| **Requested Date:** | **July 10, 2025** |
| **Requested Time:** | **5:00 P.M. Eastern Time** |

---

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, MetaVia Inc. (the **"Company"**) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-288486) (the **"Registration Statement"**) be declared effective on the "Requested Date" and at the "Requested Time" set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip D. Torrence and Joshua W. Damm of Honigman LLP, counsel to the Company, to make such request on its behalf.

Please confirm the effectiveness of the Registration Statement with Phillip D. Torrence of Honigman LLP by telephone at (269) 337-7702 or Joshua W. Damm of Honigman LLP by telephone at (313) 465-7714.

---

| |
|:---|
| Sincerely, |
| MetaVia Inc. |
| */s/* Hyung Heon Kim |
| Hyung Heon Kim |
| President, Chief Executive Officer and Director |

---

---

| | |
|:---|:---|
| cc: | Marshall Woodworth, Chief Financial Officer |
|  | **MetaVia Inc.** |
|  | Phillip D. Torrence, Esq. |
|  | Joshua W. Damm, Esq. |
|  | **Honigman LLP** |

---

[Signature Page – Acceleration Request]